LAUSR

Vitiligo is an acquired skin disorder clinically characterized by hypopigmentated macules and patches. Psoriasis is a chronic‐inflammatory‐skin‐condition characterized by erythematous‐plaques covered with scales particularly over the extensor‐surfaces, scalp, and lumbosacral region. Recent major‐researches‐advancements have significantly expanded our understanding of psoriasis‐pathophysiology, resulting in the development of highly effective targeted‐therapies, such as anti TNFα, IL‐12/23‐inhibitors, IL‐17‐inhibitors, or IL‐23‐inhibitors. Particularly, ixekizumab, a humanized‐monoclonal immunoglobulin‐G 4 antibody, specifically binding IL‐17A, demonstrated strong efficacy in threating recalcitrant psoriasis. Nevertheless, paradoxical reactions due to IL‐17 inhibitors have been described.